Skip to content
Parkinson's Disease · Essential Tremor · Dystonia · STN / GPi / VIM

Deep Brain Stimulation (DBS) in Turkey — DBS for Parkinson's, Essential Tremor, and Dystonia at Eyeglow Istanbul

Deep brain stimulation (DBS) implantation for advanced Parkinson's disease (STN or GPi targets), essential tremor (VIM thalamic), and dystonia (GPi) — coordinated through Eyeglow Health's accredited partner functional neurosurgery network at JCI-aligned hospitals in Istanbul. Medtronic Activa PC/RC, Abbott Infinity, and Boston Scientific Vercise systems available. Frame-based and robot-assisted stereotactic implantation with microelectrode recording. Honest disclosure: DBS manages motor symptoms — it does not cure Parkinson's disease and does not slow disease progression. Written candidacy assessment provided after consultation.

Request DBS candidacy evaluation Browse other treatments
Deep brain stimulation (DBS) at Eyeglow, Istanbul
Pre-op evaluation (MDS-UPDRS + L-dopa challenge)Mandatory — 2–3 day assessment
Cognitive screening pre-opNeuropsychological assessment required
Battery life (non-rechargeable)3–5 years (replacement surgery required)
Battery life (rechargeable)9–15 years (daily 1–2h charge)
Post-op programming sessions1 month, 3 months, 6 months, then annual

Verified and listed across leading directories and authorities

Verified across global platforms.
Real patient reviews, openly listed worldwide.
What it is

What is deep brain stimulation (DBS)?

Deep brain stimulation (DBS) is a neurosurgical procedure in which thin insulated electrodes (leads) are implanted in specific deep structures of the brain and connected to a battery-powered implantable pulse generator (IPG) that delivers continuous high-frequency electrical pulses to modulate abnormal neural circuit activity. DBS is the standard-of-care surgical treatment for advanced Parkinson's disease with motor fluctuations (Movement Disorder Society Guidelines 2018, NICE TA386), medically refractory essential tremor, and primary dystonia.

Critical disclosure before reading further: DBS is a symptomatic treatment. It manages specific motor symptoms — tremor, rigidity, dyskinesia, motor fluctuations — but does not slow, stop, or reverse the underlying neurodegeneration of Parkinson's disease. Axial symptoms (gait freezing, speech, swallowing, cognition, autonomic function) typically continue to progress regardless of DBS. Any claim that DBS "cures" Parkinson's disease is inaccurate.

How it works

From candidacy evaluation to long-term programming

  1. 01

    Pre-operative candidacy evaluation — MDS-UPDRS + L-dopa challenge

    DBS candidacy assessment for Parkinson's disease follows Movement Disorder Society (MDS) published criteria and NICE TA386 guidelines. The core evaluation: MDS-UPDRS (Unified Parkinson's Disease Rating Scale) motor examination in OFF state (medication withheld for 12 hours minimum) and ON state (after optimised L-dopa dose). L-dopa challenge: if the patient has at least 30% improvement in MDS-UPDRS Part III motor score from OFF to ON state — this is the primary predictor of DBS STN benefit. Patients who respond well to L-dopa respond well to STN-DBS (which mimics the dopaminergic medication effect on the subthalamic nucleus). Tremor-dominant Parkinson's may respond even without strong L-dopa response if VIM DBS is selected. For essential tremor: Fahn-Tolosa-Marin tremor rating scale, functional impact documentation, trial of propranolol and primidone, neurological confirmation of ET diagnosis.

  2. 02

    Neuropsychological assessment + cognitive screening

    Cognitive screening is a mandatory pre-operative requirement — DBS (particularly STN-DBS) is relatively contraindicated in patients with dementia or significant cognitive impairment because: (a) cognitive decline can accelerate after STN-DBS in predisposed patients; (b) awake DBS requires patient cooperation during microelectrode recording and stimulation mapping; (c) programming post-operatively requires patient feedback. Neuropsychological assessment: MMSE or MoCA (screening), followed by full neuropsychological battery if any concern (executive function, verbal memory, visuospatial function, language). Diagnosis of dementia (DSM-5 criteria) is a contraindication to DBS. Mild cognitive impairment is a relative contraindication requiring informed discussion of cognitive risk. Psychiatric evaluation: depression and anxiety are common in Parkinson's and DBS can affect mood (STN-DBS associated with risk of mania, impulsivity, and occasionally depression post-stimulation). Active untreated depression or psychosis is a contraindication until stabilised.

  3. 03

    Surgical target selection and device choice

    Surgical target determines what symptoms DBS addresses. STN (subthalamic nucleus): primary target for Parkinson's disease with motor fluctuations + dyskinesia — bilateral STN-DBS reduces "off" time, dyskinesia, and medication requirements in motor-fluctuating PD (EARLYSTIM trial, PD-SURG trial). GPi (globus pallidus internus): alternative PD target — similar motor improvement to STN but typically without medication reduction; less risk of cognitive and mood side effects; preferred in patients with significant dyskinesia, cognitive concern, or psychiatric history. GPi also primary target for dystonia. VIM (ventral intermediate nucleus): primary target for essential tremor and tremor-dominant PD — highly effective for limb tremor (70–90% tremor reduction) but does not address other PD symptoms (rigidity, bradykinesia, freezing). Device selection: Medtronic Activa PC (non-rechargeable, 3–5yr) or Activa RC (rechargeable, 9–15yr) — established, well-studied, widest worldwide physician experience. Boston Scientific Vercise Genus/Cartesia (directional leads — field shaping, rechargeable). Abbott Infinity — MRI conditional, directional stimulation, remote programming capability. Choice involves patient factors (recharging ability, MRI need, programming preference) and surgeon familiarity.

  4. 04

    DBS implantation — frame-based or robot-assisted

    Stereotactic implantation: the neurosurgeon uses a stereotactic coordinate system to place electrodes with sub-millimetre accuracy at the intended target (STN, GPi, or VIM). Frame-based stereotaxy: a rigid metal frame is attached to the patient's skull under local anaesthesia on the morning of surgery — the oldest and most-validated approach, sub-millimetre target accuracy. Frameless robot-assisted (e.g. Neuromate, Rosa, Medtronic StealthStation) — alternative modern approach, no head frame, comparable accuracy in experienced hands. Intraoperative microelectrode recording (MER): a fine microelectrode is advanced through the trajectory recording the characteristic firing patterns of neurons — STN cells have a distinctive high-frequency irregular discharge pattern that confirms the neurosurgeon is at target before placing the DBS lead. Awake DBS: the patient is awake during MER and initial test stimulation — allows real-time assessment of symptom benefit (tremor arrest, rigidity reduction) and side effect testing (tingling, dysarthria, eye deviation) to confirm optimal lead placement. Asleep DBS: under general anaesthesia with intraoperative imaging confirmation (iMRI or fluoroscopy) — avoids patient discomfort and cooperation requirements; accuracy depends on imaging confirmation rather than physiological feedback. Both approaches are accepted; centre-specific expertise and patient factors determine choice. IPG (implantable pulse generator / battery) is implanted in a second stage — typically same day (chest wall, infraclavicular) or next day.

  5. 05

    Post-operative recovery and initial programming

    Post-operative hospital stay: 3–5 days. CT head post-operatively to confirm lead position and rule out intracranial haemorrhage (reported rate 1–3%, most asymptomatic microhaemorrhages; symptomatic haematoma requiring intervention <1%). IPG activation: typically 2–4 weeks after implantation (allows surgical swelling to resolve). Initial programming session: DBS neurologist/movement disorder specialist systematically activates each contact, tests therapeutic window (minimum voltage for benefit, maximum voltage before side effect — dysarthria, dysaesthesia, diplopia), and sets initial stimulation parameters (frequency, pulse width, amplitude, contact configuration). Post-implant medication review: STN-DBS typically allows reduction of L-dopa dose — the movement disorder specialist coordinates this carefully to avoid dopaminergic reduction too rapidly (dysphoria, apathy, dopamine dysregulation syndrome management).

  6. 06

    Long-term programming and follow-up (multi-visit model)

    DBS is not a one-time intervention — the system requires ongoing programming to maintain optimal benefit as the disease progresses and stimulation effects change. Standard programming schedule: 1 month, 3 months, 6 months, then annually (or more frequently if needed). Follow-up in Istanbul: the 1-month and 3-month visits are ideally in Istanbul (or at the partner centre); subsequent programming can be performed at a DBS-capable movement disorder centre in your home country — we provide full documentation for continuity. Remote programming (Abbott Infinity, Boston Scientific Vercise with compatible hardware) allows some adjustment via smartphone-linked programmer between clinic visits. Annual battery monitoring: non-rechargeable IPG requires battery replacement surgery (minor procedure under local anaesthesia) every 3–5 years — we schedule and coordinate this within our partner network. Long-term outcome expectation: PD DBS motor benefit is maintained at 5–10 years in published data (EARLYSTIM 5-year follow-up, PD-SURG 3-year data), while the underlying disease continues to progress — axial symptoms (gait freezing, balance, falls, speech, swallowing, and cognitive symptoms) continue to worsen over time and are not reliably improved by current DBS targets.

Target and approach comparison

STN-DBS vs GPi-DBS vs VIM-DBS vs Focused Ultrasound (FUS)

The choice of DBS target and approach depends on diagnosis, symptom profile, cognitive status, and patient factors. Focused ultrasound (FUS) is a non-invasive alternative for essential tremor — coordinated through Eyeglow partner referral.

Aspect STN-DBS (Parkinson's) GPi-DBS (Parkinson's + Dystonia) VIM-DBS (Essential Tremor) Focused Ultrasound (Eyeglow partner referral)
Primary indication Advanced Parkinson's disease with motor fluctuations (wearing-off, on-off) and/or dyskinesia on optimal medication — bilateral STN-DBS reduces off-time, dyskinesia, and medication requirements Advanced Parkinson's disease — particularly with prominent dyskinesia, cognitive concern, or psychiatric history. Primary target for DYT1+ and other primary dystonia (bilateral GPi-DBS — delayed effect, 3–6 months for dystonia) Essential tremor refractory to propranolol + primidone — highly effective limb tremor suppression (70–90% reduction). Tremor-dominant PD (tremor only without significant rigidity/bradykinesia) Essential tremor — unilateral thalamic (VIM) or posterior subthalamic area lesioning with focused ultrasound; non-invasive, no implant, no anaesthesia; Eyeglow partner referral
Cognitive and mood risk Higher risk of cognitive decline in susceptible patients; neuropsychiatric effects (mania, impulsivity, depression, apathy) from dopamine dysregulation and stimulation; strict cognitive screening mandatory Lower cognitive and neuropsychiatric side effect profile than STN — preferred target for patients with cognitive concern or psychiatric history Minimal cognitive and psychiatric effects — VIM target does not affect dopaminergic circuitry; safe in cognitively impaired patients for tremor-specific treatment No implant = no hardware complications. Unilateral only — bilateral treatment causes significant ataxia and speech problems. Not suitable for bilateral ET
Medication reduction Typically allows 30–60% reduction in L-dopa equivalent dose (EARLYSTIM data) — reduces medication side effects (dyskinesia) but requires careful dopamine titration post-DBS Minimal or no medication reduction — GPi-DBS acts in parallel with medication; patient continues similar medication regime No medication change for ET; minimal effect on PD medication No medication interaction — non-pharmacological approach
MRI compatibility Device-dependent: Medtronic Activa (limited conditions — 1.5T only, head only, specific SAR limits); Abbott Infinity MR-conditional (1.5T and 3T with conditions); Boston Scientific Vercise — device specific. ALWAYS verify with implanting centre before any MRI Same device-dependent MRI conditions as STN — target does not change MRI compatibility Same device-dependent MRI conditions — device model determines compatibility, not target MRI-compatible — no implant; MRI used to guide FUS treatment in real time
Reversibility Reversible in the sense that stimulation can be turned off; DBS leads can be surgically removed (uncommon — complex, some risk); NOT reversible in the same sense as medication Same reversibility as STN Same reversibility as STN and GPi for DBS; FUS creates a permanent thermal lesion (irreversible ablation) FUS ablation is PERMANENT and IRREVERSIBLE — unilateral thalamic lesion; this is qualitatively different from DBS (stimulation can be turned off)
Pricing

Personalised pricing

Every treatment plan is priced individually after your consultation. Request a written, all-inclusive quote — clear, itemised, and with no obligation.

Request a written quote
Package transparency

What's included in your DBS coordination

Included in coordination

  • DBS candidacy evaluation: MDS-UPDRS Part III in OFF and ON state, L-dopa challenge (standardised protocol), Fahn-Tolosa-Marin tremor rating (ET)
  • Neuropsychological assessment: MoCA + full cognitive battery, psychiatric screening
  • Movement disorder specialist consultation and MDT case review
  • Written candidacy assessment with explicit statement of: DBS indication, recommended target (STN/GPi/VIM), device recommendation, predicted benefit range, and honest list of symptoms DBS is unlikely to improve
  • Pre-operative MRI brain (3T if device to be implanted permits) for surgical targeting and contraindication screening
  • DBS implantation at JCI-aligned partner hospital — functional neurosurgeon, neurophysiologist (MER), neuroanaesthesiologist
  • Microelectrode recording (MER) as standard for physiological target confirmation
  • Stereotactic frame or robot-assisted targeting (surgeon-preferred method, accuracy documented)
  • IPG implantation (device per agreed selection — Medtronic Activa, Abbott Infinity, or Boston Scientific Vercise)
  • Post-operative CT head for lead position and haemorrhage check
  • Initial DBS programming sessions in Istanbul (IPG activation, therapeutic window determination, initial parameter optimisation)
  • Full documentation package for home-country movement disorder neurologist to continue programming
  • Multilingual care coordinator — from evaluation through post-operative programming visits
  • Complication insurance policy (Türkiye Ministry of Health certified, covers surgical complications including infection, retreatment, and emergency intervention up to package value)

Quoted separately or not included

  • Device cost for Abbott Infinity or Boston Scientific Vercise where patient preference requires a specific device not in standard package — quoted separately
  • Battery replacement surgery (non-rechargeable IPG, required every 3–5 years) — quoted separately at time of need
  • Return programming visits after the initial Istanbul sessions (can be performed at a DBS-capable centre in your home country — we provide documentation)
  • Parkinson's disease medication management beyond surgical period (home-country movement disorder neurologist)
  • Physiotherapy, speech therapy, and occupational therapy post-discharge (coordinated referral to home-country provider)
  • Deep brain stimulation for OCD or treatment-resistant depression — these are experimental NICE-restricted indications requiring ethics committee approval in Turkey; we do not coordinate these outside approved research protocols
  • Focused ultrasound (FUS) thalamotomy (non-invasive alternative to VIM-DBS for ET) — Eyeglow partner referral to specialist FUS centre
  • Hotel and accommodation (quoted separately — typical stay 7–10 days for implantation + return visits)
  • Flights to/from Istanbul
  • Travel insurance (recommended — covers flight cancellation, baggage, non-surgical medical emergencies abroad; we coordinate referral if needed)
Candidacy

Are you a suitable DBS candidate?

You may be a suitable candidate if

  • You have advanced Parkinson's disease (5+ years diagnosis, on optimal medical therapy including L-dopa, experiencing significant motor fluctuations — wearing-off, on-off — or L-dopa-induced dyskinesia that limits daily function), have a positive L-dopa challenge response (30%+ MDS-UPDRS motor improvement), and have no cognitive contraindication on neuropsychological assessment.
  • You have essential tremor that is significantly disabling in daily function (writing, eating, drinking), have trialled propranolol and primidone at therapeutic doses without adequate control, and have been confirmed on neurological examination to have ET (not Holmes tremor, orthostatic tremor, or PD tremor).
  • You have primary dystonia (DYT1+ or other genetic or idiopathic dystonia) confirmed by movement disorder specialist, with significant disability, who has not responded adequately to botulinum toxin injections or oral medication.
  • You are seeking a second opinion on your DBS candidacy assessment, target selection, or device choice before proceeding with surgery.

DBS may not be appropriate if

  • You have a diagnosis of Parkinson's disease but are in early or moderate stage with good symptom control on medication and without significant motor fluctuations — DBS is not indicated at this stage (EARLYSTIM trial included patients with at least 2 years of motor complications; PRESTO and other data do not support early DBS in well-controlled PD).
  • You have significant cognitive impairment or dementia (MoCA <21 or equivalent neuropsychological finding) — DBS is relatively to absolutely contraindicated depending on severity; STN-DBS in particular carries cognitive risk in susceptible patients.
  • You have active untreated depression, psychosis, or substance misuse — psychiatric stabilisation is required before DBS evaluation.
  • You expect DBS to cure Parkinson's disease or halt disease progression — DBS controls motor symptoms (tremor, rigidity, bradykinesia, dyskinesia, off-time) but does not modify the underlying neurodegenerative process. Axial symptoms (gait freezing, balance, falls, speech, swallowing, cognition) continue to progress and are generally not improved by current DBS targets.
  • You have atypical Parkinsonism (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, Lewy body dementia) — these conditions do not respond to DBS in the same way as idiopathic PD; response is typically poor and contraindications may apply.

Disclaimer. Information on this page is consistent with Movement Disorder Society (MDS) Guidelines for DBS in Parkinson's Disease (Bronstein 2011, Okun 2014), European Academy of Neurology (EAN) DBS guidelines, and NICE Technology Appraisal TA386 (DBS for Parkinson's disease). Published clinical trial data cited: EARLYSTIM (Schuepbach 2013, NEJM), PD-SURG (Williams 2010, Lancet), VA/NIH DBS Study Group (Follett 2010, NEJM), STUMP (Stummer 2006, Lancet Oncology). Treatment decisions require assessment by a board-certified movement disorder neurologist and functional neurosurgeon with access to your full clinical records and neuropsychological evaluation.

Honest disclosure

What every DBS candidate must understand before consenting

DBS involves permanent brain implants and long-term hardware management. The following disclosures are communicated by our partner movement disorder team at every pre-operative consultation — we repeat them here so you can consider them before making contact:

DBS does NOT cure Parkinson's disease — symptom management only

This is the most important statement on this page. Deep brain stimulation for Parkinson's disease is a symptomatic treatment — it does not slow, stop, or reverse the underlying neurodegeneration. The alpha-synuclein pathology that characterises Parkinson's continues to progress regardless of DBS. What DBS does: reduces motor fluctuations (off-time, dyskinesia), improves tremor and rigidity in patients who respond well, typically allows medication reduction. What DBS does NOT do: improve speech (often worsens slightly with bilateral STN-DBS), improve swallowing, improve gait freezing in later disease, improve cognition, improve autonomic dysfunction (constipation, urinary symptoms, orthostatic hypotension), or prevent falls from postural instability. Per MDS evidence statement 2018: DBS is indicated for well-selected patients with motor fluctuations — but patients and families must understand that PD is a progressive disease and DBS addresses only a subset of the disability burden.

Hardware complications — lead fracture 1–5%, infection 3–7%, battery replacement every 3–5 years (non-rechargeable)

DBS involves implanted hardware that is subject to mechanical and biological complications over its lifespan. Lead fracture or migration: published rates 1–5% over device lifetime — requires revision surgery to reposition or replace the lead. Hardware infection: 3–7% published rate in meta-analyses (Bhatia 2018, Neurosurgery) — cellulitis at IPG pocket site or along the lead/extension cable; may require partial or complete hardware removal + antibiotic course; re-implantation possible after infection clearance. Seroma or skin erosion over IPG: 1–3%. Battery depletion (non-rechargeable IPG): requires battery replacement surgery every 3–5 years under local anaesthesia — a minor procedure but requiring return visit; 30+ year disease course = 6–10 battery replacements. Rechargeable IPG (Activa RC, Vercise, Infinity): requires daily charging 1–2 hours via external charger held over IPG site; eliminates most battery replacement surgeries but requires patient compliance and cognitive/dexterity ability to manage charging.

Surgical risk — intracranial haemorrhage 1–3%, infection 1–2%, lead misplacement

DBS implantation is a stereotactic brain procedure with a measurable perioperative risk. Intracranial haemorrhage (ICH): reported in 1–3% of cases in published meta-analyses — most are microhaemorrhages detected on post-operative imaging without clinical symptoms; symptomatic haemorrhage requiring intervention is approximately 0.5–1%. Microhaemorrhage around the lead track may cause transient neurological symptoms that resolve over days to weeks. Stroke as a consequence of surgical approach: <0.5% in experienced centres. Lead misplacement (outside target): uncommon at centres using MER and intraoperative imaging confirmation; requires revision if symptoms are suboptimal at adequate stimulation. Seizures peri-operatively: 1–3%; most transient. Death attributable to DBS surgery at experienced centres: <0.5%. General anaesthesia risk for IPG implantation applies.

MRI compatibility — not all DBS devices are compatible with all MRI conditions

MRI is essential for ongoing management of Parkinson's disease (and any other medical condition that may arise after DBS) — but MRI in a patient with DBS carries specific risks from radiofrequency energy deposition around the DBS leads, which can cause heating injury to brain tissue adjacent to the lead tip. MRI conditions vary strictly by device manufacturer and model: Medtronic Activa series — MR-conditional under specific conditions: 1.5T only, head coil only, transmit-receive head coil, specific SAR limits, specific pulse sequences only; full-body MRI is NOT permitted with most Medtronic legacy DBS systems. Abbott Infinity — MR-conditional at 1.5T and 3T (with device-specific conditions); permits a wider range of body MRI than legacy Medtronic systems. Boston Scientific Vercise Genus/Cartesia — MR-conditional at 1.5T under specific conditions. Before implantation, we discuss with you whether your future likely MRI needs (for any reason — back pain, cancer screening, other) should influence device selection. Once implanted, any MRI must be conducted ONLY at a centre that has reviewed the device documentation and operates within device-specific conditions.

OFF-medication symptoms only improve — ON-medication symptoms may not

An important and often misunderstood point about DBS outcome prediction: STN-DBS improves symptoms that respond to L-dopa in the OFF state. The L-dopa challenge is used specifically to predict DBS benefit because DBS and dopaminergic medication act through overlapping (though not identical) mechanisms at the basal ganglia level. Clinical implication: if a symptom is present in both OFF and ON medication states, DBS is unlikely to improve that symptom significantly. Examples of symptoms that are typically NOT improved by STN-DBS even in good candidates: postural instability and falls, freezing of gait in the on-state, speech, swallowing, cognition, and autonomic features. These symptoms reflect broader neurodegeneration beyond the nigrostriatal pathway (Braak staging, cholinergic, noradrenergic, autonomic involvement) and are not addressed by STN stimulation. This is communicated explicitly to every patient in the pre-operative candidacy assessment.

FAQ

Frequently asked questions about DBS in Turkey

What is deep brain stimulation (DBS)?
Deep brain stimulation (DBS) is a neurosurgical procedure in which thin insulated electrodes (leads) are implanted in specific deep structures of the brain — the subthalamic nucleus (STN), globus pallidus internus (GPi), or ventral intermediate nucleus (VIM) of the thalamus — and connected via subcutaneous extension cables to a battery-powered implantable pulse generator (IPG) implanted under the skin below the collarbone. The IPG delivers continuous electrical pulses at high frequency (typically 130–185 Hz) to the target structure, modulating abnormal neural circuit activity that causes movement disorder symptoms. DBS is reversible in the sense that stimulation can be turned off or adjusted — unlike ablative (lesioning) procedures. It is NOT reversible in a pharmacological sense, and the leads are generally left in place permanently. DBS does not cure Parkinson's disease, essential tremor, or dystonia — it manages symptoms through electrical neuromodulation of the affected circuit.

Is DBS a cure for Parkinson's disease?
No. DBS is not a cure for Parkinson's disease and does not slow or halt the underlying neurodegeneration. This is the most important clarification we make, and we make it at every patient interaction. Parkinson's disease is a progressive neurodegenerative condition — the alpha-synuclein Lewy body pathology spreads through the nervous system (Braak stages 1–6) regardless of whether DBS is implanted. DBS reduces specific motor symptoms — motor fluctuations (off-time reduction by approximately 50% in EARLYSTIM and PD-SURG trials), dyskinesia, tremor, rigidity — and typically allows meaningful medication reduction. Over time (5–10 years after implantation), the motor benefits of DBS are partially maintained in the STN-responsive symptoms while axial symptoms (gait, balance, speech, swallowing, cognition, autonomic function) continue to worsen as disease advances beyond the domain of nigrostriatal dopamine modulation. Any treatment provider who describes DBS as a "cure" for Parkinson's is not being honest with you.

Who is a suitable candidate for DBS?
DBS candidacy for Parkinson's disease follows Movement Disorder Society (MDS) published criteria (Okun 2014, Bronstein 2011) and NICE TA386. Core criteria: established diagnosis of idiopathic Parkinson's disease (not atypical Parkinsonism — MSA, PSP, CBD); disease duration typically 5+ years (diagnosis certainty); on optimised dopaminergic therapy (L-dopa and/or dopamine agonist at maximum tolerated doses); significant motor fluctuations — wearing-off (loss of dose effectiveness before next dose), on-off oscillations, or L-dopa-induced dyskinesia that limits quality of life; positive L-dopa challenge response (30%+ improvement in MDS-UPDRS Part III motor score OFF to ON); absence of cognitive contraindication (no dementia, mild cognitive impairment is a relative contraindication with shared decision making); absence of active psychiatric contraindication; realistic understanding of what DBS can and cannot achieve; ability to attend follow-up programming visits (or commitment to organise this locally). For essential tremor: disabling tremor (rating scale + functional impact), failed trial of two medications (propranolol + primidone first-line), confirmed ET diagnosis (not Holmes, orthostatic, or PD tremor).

What is the difference between STN-DBS and GPi-DBS for Parkinson's?
STN-DBS (subthalamic nucleus target) and GPi-DBS (globus pallidus internus target) are the two established surgical targets for Parkinson's disease DBS. They have broadly similar motor efficacy but differ in important secondary characteristics. STN-DBS: typically achieves greater reduction in L-dopa equivalent dose (30–60% medication reduction) — which is advantageous in patients with medication side effects. However STN-DBS carries a higher risk of neuropsychiatric side effects (impulsivity, mania, hypersexuality from dopamine dysregulation syndrome as medication is reduced; emotional lability; depression). STN-DBS may be more effective for bradykinesia and off-state symptoms. GPi-DBS: achieves similar motor improvement to STN-DBS without the same degree of medication reduction. Lower risk of neuropsychiatric effects — preferred in patients with cognitive vulnerability, depression, psychiatric history, or complex medication regimes where dopamine dose reduction is risky. GPi is also the primary target for dystonia, where bilateral GPi-DBS is evidence-based (response may take 3–6 months). The VA/NIH DBS Study Group (CSP 468, NEJM 2016) directly compared STN vs GPi DBS in a randomised controlled trial — found comparable motor outcomes at 24 months with different side-effect profiles. Target selection is individualised by the movement disorder MDT.

What is awake DBS vs asleep DBS?
Awake DBS is the traditional approach: after frame placement under local anaesthesia, the patient is awake in the operating theatre while the neurosurgeon advances microelectrodes through the brain, recording characteristic firing patterns that confirm target localisation (microelectrode recording — MER). The patient receives test stimulation to confirm therapeutic benefit (tremor arrest, rigidity reduction) and absence of stimulation-induced side effects (tingling, dysarthria, eye deviation from internal capsule — confirming the electrode is medial enough). Awake DBS requires patient cooperation and communication for 2–4 hours. Asleep DBS (under general anaesthesia): the patient is asleep throughout; target confirmation relies on intraoperative imaging (CT, MRI, fluoroscopy) rather than physiological MER. Published comparative data suggests comparable lead accuracy and clinical outcomes between awake and asleep DBS in experienced hands (Mirzadeh 2016, Anaesth 2019 meta-analysis). Asleep DBS is preferred for patients with severe anxiety, claustrophobia, marked motor fluctuations (can't remain still), severe tremor during awake period, or cognitive impairment limiting cooperation. Our partner functional neurosurgeon performs both approaches — the recommended approach is discussed at the pre-operative planning meeting.

What is the battery replacement schedule and what does it involve?
DBS requires a battery (IPG — implantable pulse generator) that depletes over time. Battery life depends on stimulation parameters and device type. Non-rechargeable IPG (Medtronic Activa PC, some Boston Scientific): typical lifespan 3–5 years at standard PD stimulation settings; may be shorter with high-energy stimulation (large amplitude, wide pulse width) or longer with low-parameter tremor settings. Battery replacement is a surgical procedure under local anaesthesia (30–45 minutes): the IPG pocket in the chest wall is reopened, the depleted IPG is disconnected and removed, the new IPG is connected to the existing leads (which remain in the brain — no brain surgery required for battery replacement), and the wound is closed. Risk profile is low: infection risk 1–3%, haematoma <1%. Rechargeable IPG (Medtronic Activa RC, Abbott Infinity, Boston Scientific Vercise): designed to last 9–15 years; requires daily recharging at home (1–2 hours using an external charger held over the IPG site). The rechargeable option eliminates most battery replacement surgeries over the disease course — significant advantage given that PD has a 20–30+ year course in many patients. Patient factors for rechargeable: dexterity to manage charger (tremor may make this difficult), cognitive ability to manage charging routine, caregiver support if independent management is not possible.

Can I have an MRI after DBS surgery?
Yes, but only under specific conditions that depend entirely on your implanted device model and version. DBS is not an absolute contraindication to MRI, but it creates significant restrictions. Medtronic Activa PC/RC legacy systems: MR-conditional under highly specific conditions — 1.5T only, head transmit-receive coil only, SAR-restricted pulse sequences only (FLASH, TSE/FSE sequences), cannot undergo full-body MRI (abdomen, spine, pelvis) with most legacy Medtronic systems. Abbott Infinity SCS/DBS systems: broader MRI compatibility — MR-conditional at 1.5T and 3T under specific conditions, permits some body MRI zones (check specific system documentation). Boston Scientific Vercise Genus/Cartesia: 1.5T conditional under specific conditions. Practical implications: if you have an ongoing cancer diagnosis requiring regular body CT or PET-CT (not MRI), DBS restrictions are manageable. If you have a family history of cancer or other conditions likely to require MRI of the spine or abdomen, discuss this with your DBS team at implant selection — device choice may be influenced by anticipated future MRI needs. After implantation, carry your device ID card at all times and ensure any treating clinician (emergency department, oncology, orthopaedics) is aware of your DBS system before ordering any MRI.

How many programming sessions will I need after surgery?
DBS programming is a multi-session, multi-month process — the optimal stimulation settings are not known at implantation and require iterative adjustment. Standard schedule at Eyeglow Health and our partner centre: pre-discharge session (contact testing, initial parameters), 1-month post-operative session (first full programming, L-dopa dose adjustment begins), 3-month session (parameter refinement, medication optimisation), 6-month session (often the session when settings reach near-optimum; medication reduction completed). After 6 months: annually or as needed for parameter drift, battery monitoring, or clinical change. After the Istanbul-based sessions (1-month and 3-month minimum), programming can continue at a DBS-capable movement disorder centre in your home country — we provide full device documentation, parameter history, and treating neurologist summary. Some newer DBS systems (Abbott Infinity, Boston Scientific) support remote programming via smartphone-linked programmer — allows incremental parameter adjustment between clinic visits within predefined limits set by your DBS neurologist. Programming for dystonia follows a different timeline: GPi-DBS for dystonia has delayed effect (3–6 months for full benefit), requiring patience and regular assessment rather than rapid titration.

What symptoms will DBS NOT improve in Parkinson's disease?
This is one of the most critical questions to address before DBS, because unrealistic expectations are a primary cause of post-operative dissatisfaction. Symptoms that DBS (particularly STN-DBS) typically does NOT reliably improve: postural instability and falls — related to non-dopaminergic pathways (cholinergic, cerebellar, proprioceptive); one of the most disabling later-stage PD symptoms; falls may actually worsen as medication is reduced; freezing of gait in the medication ON state — freezing in the off-state typically responds well, but on-state freezing is a different physiological phenomenon poorly responsive to DBS or medication; speech difficulties (dysarthria, hypophonia) — often worsens slightly with bilateral STN-DBS; some patients benefit from unilateral or carefully positioned GPi stimulation; swallowing dysfunction (dysphagia) — progressive; DBS does not address the bulbar involvement of advancing PD; cognitive decline and dementia — DBS does not prevent or reverse cognitive progression; STN-DBS may accelerate cognitive decline in patients with pre-existing mild cognitive impairment; autonomic dysfunction (constipation, bladder urgency, orthostatic hypotension, sexual dysfunction) — involves enteric and autonomic nervous system; not addressed by DBS. Patients and families must receive this information before consent.

What is focused ultrasound (FUS) and how is it different from DBS?
Focused ultrasound thalamotomy (FUS) is an alternative to VIM-DBS for essential tremor — it uses a phased array of ultrasound transducers focused to a 4–5 mm spot in the VIM thalamus, creating a thermal lesion (ablation) that permanently destroys the targeted cells. Published efficacy: the NEJM 2016 randomised controlled trial (Elias 2016) showed 47% improvement in tremor scores vs 0% in sham at 3 months. Key differences vs DBS: FUS is non-invasive (no brain surgery, no anaesthesia, no scalp incision) — significant advantage for elderly or high surgical risk patients. FUS is permanent and irreversible — unlike DBS stimulation which can be adjusted or turned off. FUS is currently approved for unilateral treatment only (one side of the brain) — bilateral FUS causes severe ataxia and dysarthria (acceptable for most patients with unilateral dominant-hand tremor, but limits treatment of bilateral severe ET). DBS can be implanted bilaterally with programming flexibility. FUS requires adequate skull density ratio (SDR) — patients with low SDR (typically due to osteoporosis or prior skull procedures) cannot be treated; CT scan-based skull characterisation is required before FUS candidacy confirmation. At Eyeglow Health, FUS is coordinated through our partner referral network for patients who are better candidates for the non-invasive approach.

Why choose Eyeglow Health for DBS coordination?
Eyeglow Health's primary clinical specialty is ophthalmology. We coordinate DBS through our accredited partner network because patients seeking DBS in Turkey need the same infrastructure we provide for our core treatments — a named care coordinator, written candidacy assessment with honest outcome expectations, complication insurance, and a framework of responsibility that does not disappear after the surgical fee is paid. Our partner functional neurosurgeon holds documented DBS implantation volume (bilateral PD, ET, dystonia cases), with neuronavigation and MER infrastructure at a JCI-aligned hospital. We will tell you honestly if your case is not appropriate for DBS — if your cognitive screening shows contraindication, if your L-dopa challenge shows insufficient response, if you have atypical Parkinsonism that does not respond to DBS, or if your care is better served by a specialist movement disorder centre at home. Programming sessions post-implantation can continue in Istanbul or be transferred to your home-country neurologist with full documentation — we design care for the long term, not just the surgical episode.

What is the difference between DBS and ablative surgery (pallidotomy, thalamotomy)?
Ablative procedures (pallidotomy for PD/dyskinesia, thalamotomy for tremor) involve deliberately destroying a small volume of targeted brain tissue to interrupt the abnormal circuit. They were the primary surgical treatment for movement disorders before DBS became established in the 1990s. DBS does not destroy tissue — it modulates neural activity through electrical stimulation and its effects can be reversed by turning off the device. Ablative procedures are permanent and irreversible. The advantage of ablation is no implanted hardware (no battery, no lead fracture, no infection risk, no MRI restrictions). Modern ablation: stereotactic radiosurgery (Gamma Knife thalamotomy) and focused ultrasound thalamotomy are non-invasive methods to create precise ablative lesions — these avoid open surgery risk. For bilateral treatment of Parkinson's disease, bilateral ablation carries prohibitive risk of dysarthria, cognitive effects, and pseudobulbar symptoms — bilateral DBS is generally preferred. For unilateral essential tremor in appropriate patients, focused ultrasound or Gamma Knife thalamotomy is an evidence-based alternative to VIM-DBS with comparable efficacy and no implant-related complications.
Request evaluation